SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after reports surfaced of a potential partnership with Novo Nordisk to distribute GLP-1 obesity drugs, signaling an end to their prior legal dispute. This development has ignited fervent community discussion about a massive short squeeze due to the stock's high short interest and its strengthened position in the digital health market.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after forming a partnership with Hims & Hers to distribute its obesity drugs, ending a prior feud and surprising the community. This, alongside reports of rapidly accelerating oral Wegovy prescriptions and an FDA crackdown on compounded GLP-1s, is driving discussion that the stock is oversold despite ongoing competitive dynamics with Eli Lilly.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure NV is surging on high volume as the community speculates a massive short squeeze and a bullish sentiment shift, following news of a key FDA official's impending departure, which is seen as favorable for gene therapies like QURE's Huntington's therapy. This is amplified by discussions of a newly clarified, less burdensome regulatory path for their lead asset and a technical rebound from oversold conditions.

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

Savara is trending following the FDA's Day 74 Letter confirming MOLBREEVI's Biologics License Application is under full review with a PDUFA target action date of August 22, 2026, and no advisory committee meeting planned. The community sees this as a positive step towards Molbreevi becoming a first-in-class therapy for autoimmune PAP, fueling optimism around its market potential and future valuation.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating U.S.-Iran tensions have severely disrupted oil tanker traffic through the Strait of Hormuz, propelling crude prices higher. The community is split between calls for further parabolic gains to $150-$200 due to broken supply chains and warnings of a manipulated "blow-off top" and imminent correction, with broader concerns about inflation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as its CEO hints at "curative outcomes" for AML, sparking community excitement about groundbreaking efficacy and a potential short squeeze, with further anticipation from an ongoing oncology summit. The prolonged duration of its pivotal REGAL trial, indicating patients are living longer than expected, reinforces investor belief in the drug's transformative potential beyond disease management.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is driving intense conversation, fueled by fresh reports of potential Nvidia chip exports to China and strong AI demand outlooks from semiconductor giants, though community sentiment is sharply divided. While many view the sector as an unstoppable "infinite money glitch" in the AI boom, others warn of an impending "bubble" due to stretched valuations and recent underperformance against software ETFs.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is trending due to recent mixed earnings results showing revenue growth but sparking community concerns about financial stability and potential dilution, even as its "game-changing" 365-day CGM system gains regulatory approvals and integrates with automated insulin delivery. This creates intense shareholder debate, with many praising the superior technology while criticizing management's ability to effectively commercialize the product and questioning the company's long-term strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMC plans free perk for loyal customers amid struggles

AMC Theatres, the top movie chain in the U.S., continues to struggle with weak consumer demand even after several blockbuster releases. To combat these challenges, AMC plans to make its loyalty...

National CineMedia, Inc. (NASDAQ:NCMI) Announces Quarterly Dividend of $0.03

National CineMedia, Inc. (NASDAQ:NCMI) announced a quarterly dividend on Thursday, February 26th. Shareholders of record on Monday, March 9th will be given a dividend of 0.03 per share by the...

National CineMedia Inc. Q4 Income Climbs

(RTTNews) - National CineMedia Inc. (NCMI) released a profit for its fourth quarter that Increases, from the same period last year...

National CineMedia Q4 Earnings Call Highlights

National CineMedia (NASDAQ:NCMI) executives told investors the company made meaningful progress in 2025 by investing in its advertising platform, expanding inventory access through programmatic and...

National CineMedia (NCMI) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for National CineMedia (NCMI) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

National CineMedia (NASDAQ:NCMI) Posts Earnings Results, Beats Estimates By $0.02 EPS

National CineMedia (NASDAQ:NCMI - Get Free Report) posted its earnings results on Thursday. The business services provider reported $0.28 earnings per share for the quarter, topping analysts...

National CineMedia (NCMI) Q4 Earnings and Revenues Top Estimates

National CineMedia (NCMI) delivered earnings and revenue surprises of +10.54% and +2.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

National CineMedia, Inc. Reports Results for Fiscal Fourth Quarter and Full Year 2025

National CineMedia, Inc. (NASDAQ: NCMI) (the Company or NCM), the managing member of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising platform in the U.S., announced...

A Peek at National CineMedia's Future Earnings

National CineMedia (NCMI) to Release Quarterly Earnings on Thursday

National CineMedia (NASDAQ:NCMI) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

National CineMedia, Inc. is a holding company which engages in the provision of various advertising, business meetings, event services, and third-party theatre circuits under network affiliate agreements. It mainly operates as a cinema advertising platform. National CineMedia was founded on October 5, 2006 and is headquartered in Centennial, CO.

Current Price	$3.55
Prev Close	$3.50
Open	$3.42
Dividend Yield	3.08%
50-Day Moving Average	$3.65
Beta	1.03
Avg. Volume	534,945.39
PE Ratio	-32.99

52-Week High	$6.18
52-Week Low	$3.17
Market Capitalization	$326M
EPS (Annual)	-$0.1126
Price to Book	0.87
Revenue Per Employee	$980,645.16

NCMI
National Cinemedia Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NCMI News

NCMINational Cinemedia Inc